既往疟疾暴露血清学标志与抑制寄生虫生长的功能性抗体同控制性人疟感染后原虫动力学相关
研究比较既往疟疾高暴露与低暴露两组成人接受3200个恶性疟原虫子孢子接种后的原虫动力学与功能免疫。低暴露组全部9人、高暴露组7/9人经厚血涂片检出原虫血症,低暴露组中位至原虫血症时间显著更短;高暴露组子孢子抗体识别与生长抑制活性均显著更高。
要点
- 既往疟疾高暴露者接种后至原虫血症中位时间更长(11.0天 vs 9天)。
- 高暴露组子孢子抗体识别中位17.93 AU,显著高于低暴露组10.54 AU。
- 高暴露组生长抑制活性中位21.8%,显著高于低暴露组8.3%。
核心结论
- 既往疟疾暴露血清学证据较高者能更好地控制感染,并具有更高的原虫生长抑制活性。
研究设计与样本
- 研究纳入9名既往高暴露(sero-high)与10名低暴露(sero-low)的成年男性,经直接静脉接种3200个恶性疟原虫子孢子(PfSPZ),随访35天,以厚血涂片和定量PCR检测原虫血症。
主要发现
- 低暴露组10/10(100%)与高暴露组7/9(77.8%)在接种后28天内经厚血涂片检出原虫血症(P = .125)。
- 低暴露组至原虫血症中位时间显著短于高暴露组(9天[IQR 7.5-11.0] vs 11.0天[IQR 7.5-18.0];log-rank检验P = .005)。
- 高暴露组子孢子抗体识别中位17.93 AU(IQR 12.95-24)显著高于低暴露组中位10.54 AU(IQR 8.36-12.12)(P = .006)。
- 高暴露组生长抑制活性中位21.8%(IQR 8.15%-29.65%)显著高于低暴露组中位8.3%(IQR 5.6%-10.23%)(P = .025)。
关键数值与推荐
- 原虫血症检出率:低暴露组10/10(100%),高暴露组7/9(77.8%),P = .125。
- 至原虫血症中位时间:低暴露组9天(IQR 7.5-11.0),高暴露组11.0天(IQR 7.5-18.0),P = .005。
- 子孢子抗体识别中位值:高暴露组17.93 AU(IQR 12.95-24),低暴露组10.54 AU(IQR 8.36-12.12),P = .006。
- 生长抑制活性中位值:高暴露组21.8%(IQR 8.15%-29.65%),低暴露组8.3%(IQR 5.6%-10.23%),P = .025。
临床怎么用
- 在评估疟疾暴露史时,可参考血清学标志与功能抗体水平判断个体对感染的控制能力。
- 控制性人疟感染(CHMI)在该人群中安全且耐受良好,可用于研究功能免疫。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We assessed the impact of exposure to Plasmodium falciparum on parasite kinetics, clinical symptoms, and functional immunity after controlled human malaria infection (CHMI) in 2 cohorts with different levels of previous malarial exposure. METHODS: Nine adult males with high (sero-high) and 10 with low (sero-low) previous exposure received 3200 P. falciparum sporozoites (PfSPZ) of PfSPZ Challenge by direct venous inoculation and were followed for 35 days for parasitemia by thick blood smear (TBS) and quantitative polymerase chain reaction. Endpoints were time to parasitemia, adverse events, and immune responses. RESULTS: Ten of 10 (100%) volunteers in the sero-low and 7 of 9 (77.8%) in the sero-high group developed parasitemia detected by TBS in the first 28 days (P = .125). The median time to parasitemia was significantly shorter in the sero-low group than the sero-high group (9 days [interquartile range {IQR} 7.5-11.0] vs 11.0 days [IQR 7.5-18.0], respectively; log-rank test, P = .005). Antibody recognition of sporozoites was significantly higher in the sero-high (median, 17.93 [IQR 12.95-24] arbitrary units [AU]) than the sero-low volunteers (median, 10.54 [IQR, 8.36-12.12] AU) (P = .006). Growth inhibitory activity was significantly higher in the sero-high (median, 21.8% [IQR, 8.15%-29.65%]) than in the sero-low group (median, 8.3% [IQR, 5.6%-10.23%]) (P = .025). CONCLUSIONS: CHMI was safe and well tolerated in this population. Individuals with serological evidence of higher malaria exposure were able to better control infection and had higher parasite growth inhibitory activity. CLINICAL TRIALS REGISTRATION: NCT03496454.
引用
- Achan J, Reuling IJ, Yap XZ, et al. Serologic Markers of Previous Malaria Exposure and Functional Antibodies Inhibiting Parasite Growth Are Associated With Parasite Kinetics Following a Plasmodium falciparum Controlled Human Infection. Clin Infect Dis. 2020. PMID: 31402382. doi:10.1093/cid/ciz740
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。